Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of RAS/BRAF mutation status in locally advanced rectal cancer treated with preoperative chemotherapy.

International journal of clinical oncology - 1 Aug 2018

Oshiro Taihei, Uehara Keisuke, Aiba Toshisada, Mukai Toshiki, Ebata Tomoki, Nagino Masato

Abstract excerpt

PURPOSE: Our sincere hope is to establish the predictive factors of neoadjuvant chemotherapy (NAC) response and provide patients with greater certainty regarding treatment outcomes. The aim of this study was to assess the response to NAC and survival in patients with locally advanced rectal cancer (LARC) according to their RAS/BRAF mutation status. METHODS: Data on 57 patients with LARC who received NAC between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Neoadjuvant Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Preoperative Care

Share to Proto-Oncogene Proteins B-raf

Share to ras Proteins

Share to Rectal Neoplasms

Share to Survival Rate

Source

Identifiers

PMID: 29478127
DOI: 10.1007/s10147-018-1253-z

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of RAS/BRAF mutation status in locally advanced rectal cancer treated with preoperative chemotherapy.PMID 29478127Read ↗

Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety.Semantic proximity Read ↗

Prognostic Impact of Ras Mutation on Surgical Strategy in Rectal Cancer Patients Undergoing Neoadjuvant Treatment.Semantic proximity Read ↗

Association Between RAS/BRAF Mutations and Complete Response Following Total Neoadjuvant Therapy in Patients with Rectal Cancer: A Prospective Multicentered Study.Semantic proximity Read ↗

Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer.Semantic proximity Read ↗

Pathological Response Has Survival Benefits for Rectal Cancer following Neoadjuvant TherapySemantic proximity Read ↗

KRAS Mutant Status May Be Associated with Distant Recurrence in Early-stage Rectal Cancer.Semantic proximity Read ↗

Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery.Semantic proximity Read ↗

KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis.Semantic proximity Read ↗

Factors Affecting Survival Prognosis of Patients with Rectal Cancer After Neoadjuvant ChemoradiotherapySemantic proximity Read ↗

The prognostic value of KRAS mutation in locally advanced rectal cancer.Semantic proximity Read ↗

The prognostic value of KRAS mutation in locally advanced rectal cancer.Semantic proximity Read ↗

A Genotype Signature for Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.